Sanofi Receives European Commission Approval for Sarclisa Combination Therapy in Newly Diagnosed Multiple Myeloma
Monday, November 17, 2025
Sanofi has announced today that it has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as an induction treatment for adults newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant. This marks a significant milestone in the European regulatory landscape for multiple myeloma therapies, positioning Sarclisa as a key component in frontline treatment regimens for eligible patients.
The approval is based on robust clinical data from the phase III GMMG-MM5 trial, which demonstrated that the addition of Sarclisa to VRd significantly improved progression-free survival compared to VRd alone. The trial included a large cohort of European patients, underscoring the relevance of the data for European healthcare providers and regulatory authorities. The results showed a statistically significant reduction in the risk of disease progression or death, reinforcing the clinical value of this combination therapy in the European context.
Multiple myeloma remains one of the most challenging hematological malignancies, with a high unmet need for effective frontline therapies that can improve long-term outcomes. The approval of Sarclisa in combination with VRd offers a new standard of care for newly diagnosed patients, potentially transforming treatment pathways across Europe. This development is particularly significant given the increasing focus on personalized and combination therapies in hematology, as well as the growing emphasis on improving patient outcomes through innovative drug regimens.
From a regulatory perspective, the European Commission’s decision reflects the ongoing commitment to accelerating the availability of novel therapies for patients with high unmet medical needs. The approval process was supported by comprehensive data submissions, including efficacy, safety, and pharmacokinetic profiles, which were rigorously reviewed by the European Medicines Agency (EMA). The decision also highlights the importance of collaboration between pharmaceutical companies, regulatory authorities, and clinical investigators in advancing the development of new treatments for complex diseases.
For Sanofi, this approval represents a strategic expansion of its oncology portfolio in Europe, reinforcing its position as a leader in the development and commercialization of innovative therapies for hematological malignancies. The company has indicated that it will work closely with healthcare providers, payers, and patient advocacy groups to ensure rapid access to Sarclisa for eligible patients across Europe. This includes supporting the implementation of appropriate treatment guidelines, providing educational resources for healthcare professionals, and facilitating patient access programs where needed.
The approval also has broader implications for the European pharmaceutical industry, as it sets a precedent for the integration of monoclonal antibodies into frontline treatment regimens for multiple myeloma. This could stimulate further research and development in the field, encouraging other companies to explore similar combination approaches for other hematological malignancies. Additionally, the decision may influence future regulatory strategies for other novel therapies seeking approval in Europe, particularly those targeting high unmet medical needs.
In summary, Sanofi’s approval of Sarclisa in combination with VRd for newly diagnosed multiple myeloma patients represents a major advancement in European oncology care. It underscores the importance of innovative drug development, robust clinical evidence, and effective regulatory collaboration in improving patient outcomes. As the European pharmaceutical landscape continues to evolve, this approval serves as a benchmark for future therapies aiming to address complex and challenging diseases.
